The tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) induces apoptosis of tumor cells but not normal cells; its role in normal nontransformed tissues is unknown. We report here that chronic blockade of TRAIL in mice exacerbated autoimmune arthritis, and that intraarticular TRAIL gene transfer ameliorated the disease. In vivo, TRAIL blockade led to profound hyperproliferation of synovial cells and arthritogenic lymphocytes and heightened the production of cytokines and autoantibodies. In vitro, TRAIL inhibited DNA synthesis and prevented cell cycle progression of lymphocytes. Interestingly, TRAIL had no effect on apoptosis of inflammatory cells either in vivo or in vitro. Thus, unlike other members of the tumor necrosis factor superfamily, TRAIL is a prototype inhibitor protein that inhibits autoimmune inflammation by blocking cell cycle progression.
Skip Nav Destination
Article navigation
3 April 2000
Article|
March 27 2000
Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Is an Inhibitor of Autoimmune Inflammation and Cell Cycle Progression
Kaimei Song,
Kaimei Song
aDepartment of Molecular and Cellular Engineering, Institute for Human Gene Therapy, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
Search for other works by this author on:
Yiguang Chen,
Yiguang Chen
aDepartment of Molecular and Cellular Engineering, Institute for Human Gene Therapy, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
Search for other works by this author on:
Rüdiger Göke,
Rüdiger Göke
aDepartment of Molecular and Cellular Engineering, Institute for Human Gene Therapy, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
Search for other works by this author on:
Andreas Wilmen,
Andreas Wilmen
aDepartment of Molecular and Cellular Engineering, Institute for Human Gene Therapy, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
Search for other works by this author on:
Cheryl Seidel,
Cheryl Seidel
aDepartment of Molecular and Cellular Engineering, Institute for Human Gene Therapy, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
Search for other works by this author on:
Alexandra Göke,
Alexandra Göke
aDepartment of Molecular and Cellular Engineering, Institute for Human Gene Therapy, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
Search for other works by this author on:
Brendan Hilliard,
Brendan Hilliard
aDepartment of Molecular and Cellular Engineering, Institute for Human Gene Therapy, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
Search for other works by this author on:
Youhai Chen
Youhai Chen
aDepartment of Molecular and Cellular Engineering, Institute for Human Gene Therapy, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
Search for other works by this author on:
Kaimei Song
aDepartment of Molecular and Cellular Engineering, Institute for Human Gene Therapy, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
Yiguang Chen
aDepartment of Molecular and Cellular Engineering, Institute for Human Gene Therapy, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
Rüdiger Göke
aDepartment of Molecular and Cellular Engineering, Institute for Human Gene Therapy, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
Andreas Wilmen
aDepartment of Molecular and Cellular Engineering, Institute for Human Gene Therapy, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
Cheryl Seidel
aDepartment of Molecular and Cellular Engineering, Institute for Human Gene Therapy, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
Alexandra Göke
aDepartment of Molecular and Cellular Engineering, Institute for Human Gene Therapy, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
Brendan Hilliard
aDepartment of Molecular and Cellular Engineering, Institute for Human Gene Therapy, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
Youhai Chen
aDepartment of Molecular and Cellular Engineering, Institute for Human Gene Therapy, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
Abbreviations used in this paper: Ad, adenovirus; AICD, activation-induced cell death; ANOVA, analysis of variance; BrdU, bromodeoxyuridine; DR, death receptor; DcR, decoy receptor; HE, hematoxylin and eosin; HSA, human serum albumin; L, ligand; NF, nuclear factor; s, soluble; TRAIL, tumor necrosis factor–related apoptosis-inducing ligand.
Received:
December 13 1999
Revision Requested:
February 10 2000
Accepted:
February 17 2000
Online ISSN: 1540-9538
Print ISSN: 0022-1007
© 2000 The Rockefeller University Press
2000
The Rockefeller University Press
J Exp Med (2000) 191 (7): 1095–1104.
Article history
Received:
December 13 1999
Revision Requested:
February 10 2000
Accepted:
February 17 2000
Citation
Kaimei Song, Yiguang Chen, Rüdiger Göke, Andreas Wilmen, Cheryl Seidel, Alexandra Göke, Brendan Hilliard, Youhai Chen; Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Is an Inhibitor of Autoimmune Inflammation and Cell Cycle Progression. J Exp Med 3 April 2000; 191 (7): 1095–1104. doi: https://doi.org/10.1084/jem.191.7.1095
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement